Abstract: A wireless communication network wirelessly receives a slice indicator from a wireless communication device. The wireless communication network selects an Artificial Intelligence (AI) engine based on the slice indicator. The wireless communication network may select the AI engine by selecting a wireless network slice that comprises the AI engine based on the slice indicator. The wireless communication network wirelessly receives user data from the wireless communication device for the wireless network slice. The wireless communication network transfers the user data to the selected AI engine. The selected AI engine generates an AI output based on the user data.

Abstract: A wireless communication system generates Artificial Intelligence (AI) responses to network data. Computer circuitry hosts network functions, distributed ledgers, ledger clients, and AI engines. The network functions serve User Equipment (UEs) over Radio Access Networks (RANs), and in response, transfer the network data to the distributed ledgers. The distributed ledgers receive and store the network data. The ledger clients select some of the network data from the distributed ledgers and transfer the selected network data to the AI engines. The AI engines receive the selected network data, and in response, generate the AI responses. The ledger clients and the AI engines may comprise wireless network slices.

Abstract: A wireless communication system generates Artificial Intelligence (AI) responses to network data. Computer circuitry hosts network functions, distributed ledgers, ledger clients, and AI engines. The network functions serve User Equipment (UEs) over Radio Access Networks (RANs), and in response, transfer the network data to the distributed ledgers. The distributed ledgers receive and store the network data. The ledger clients select some of the network data from the distributed ledgers and transfer the selected network data to the AI engines. The AI engines receive the selected network data, and in response, generate the AI responses. The ledger clients and the AI engines may comprise wireless network slices.

Abstract: A data communication system generates Artificial Intelligence (AI) responses to distributed ledger data. In the data communication system, ledger clients discover distributed ledgers and establish hardware-trust with the distributed ledgers. The ledger clients discover AI engines and establish hardware-trust with the AI engines. The ledger clients read ledger information from the top data blocks of the distributed ledgers and select top-block ledger information. The ledger clients select AI engines to receive the selected top-block ledger information and transfer the selected ledger information to the selected AI engines. The selected AI engines process the selected top-block ledger information and generate the AI responses.

Abstract: A Network Function Virtualization Infrastructure (NFVI) executes Virtual Network Functions (VNFs) to transfer the VNF boot data to a distributed ledger. The distributed ledger performs a distributed ledger transaction with the VNF boot data to commit the VNF boot data to distributed ledger memory in a blockchain format. The NFVI executes the network VNF to deliver a network communication service. The NFVI loses VNF boot functionality and transfers a VNF boot request to the distributed ledger. The distributed ledger performs a distributed ledger transaction with the VNF boot request and the VNF boot data to transfer VNF recovery data to the NFVI and to commit the VNF boot request and the VNF recovery data to the distributed ledger memory in the blockchain format. The NFVI processes the VNF recovery data to recover the VNF boot functionality. The NFVI executes the recovered VNF to deliver the network communication service.

Abstract: The present invention provides compounds of Formula (I): (Formula (I), or a stereoisomer, or a pharmaceutically acceptable salt thereof, wherein all of the variables are as defined herein. These compounds are GPR40 G protein-coupled receptor modulators which may be used as medicaments.

Abstract: The present invention provides compounds of Formula (I): (Formula (I), or a stereoisomer, or a pharmaceutically acceptable salt thereof, wherein all of the variables are as defined herein. These compounds are GPR40 G protein-coupled receptor modulators which may be used as medicaments.

Abstract: A calling type identification system selects a calling type. The system selects NPA-NXX telephone number blocks for the calling type based on NPA-NXX block categories related to the calling type. The system develops number data for the selected NPA-NXX telephone number blocks. The system receives a telephone number for a call. The system processes the telephone number and the number data to identify and indicate if the telephone call is of the selected calling type.

Abstract: Novel compounds are provided which are 1 1-beta-hydroxysteroid dehydrogenase type I inhibitors. 1 1-beta-hydroxysteroid dehydrogenase type I inhibitors are useful in treating, preventing, or slowing the progression of diseases requiring 1 1-beta-hydroxysteroid dehydrogenase type I inhibitor therapy. These novel compounds have the structure: W-L-Z or stereoisomers or prodrugs or pharmaceutically acceptable salts thereof, wherein W, L are defined herein and Z is selected from the following bicyclic heteroaryl groups: (a), (b), (c), (d).

Abstract: Novel compounds are provided which are 1 1-beta-hydroxysteroid dehydrogenase type I inhibitors. 1 1-beta-hydroxysteroid dehydrogenase type I inhibitors are useful in treating, preventing, or slowing the progression of diseases requiring 1 1-beta-hydroxysteroid dehydrogenase type I inhibitor therapy. These novel compounds have the structure: W-L-Z or stereoisomers or prodrugs or pharmaceutically acceptable salts thereof, wherein W, L are defined herein and Z is selected from the following bicyclic heteroaryl groups: (a), (b), (c), (d).

Abstract: Compounds are provided having the formula: wherein R1, R2, R2?, R3, R3?, R4, R4?, R5, X, Y and Z are as defined herein.

Abstract: Compounds are provided having the following structure and pharmaceutically acceptable salts thereof, wherein R1, R2, R3, R4, U, V, W, Y, and n are as defined above, which compounds are HMG CoA reductase inhibitors and thus are active in inhibiting cholesterol biosynthesis, modulating blood serum lipids, for example, lowering LDL cholesterol and/or increasing HDL cholesterol, and treating hyperlipidemia, dyslipidemia, hypercholesterolemia, hypertriglyceridemia and atherosclerosis as well as Alzheimer's disease and osteoporosis and may be employed as hormone replacement therapy. A method for treating the above diseases employing the above compounds is also provided.

Abstract: Sulfonamide lactams of the following formula wherein X, R1, R2, R3, R4, R4a, R5, R5a, R6, R6a, R7 and R8 are as described herein, are provided which inhibitors of Factor Xa and are useful as anticoagulants in the treatment of cardiovascular diseases associated with thromboses.

Abstract: Sulfonamide lactams of the following formula 1

Abstract: Sulfonamide lactams of the following formula wherein X, R1, R2, R3, R4, R4a, R5, R5a, R6, R6a, R7 and R8 are as described herein, are provided which inhibitors of Factor Xa and are useful as anticoagulants in the treatment of cardiovascular diseases associated with thromboses.

Abstract: Lactam inhibitors are provided which have the structure including pharmaceutically acceptable salts thereof and all stereoisomers thereof, and prodrug esters thereof, wherein n is 1 to 5; and and R1, R2, R3, R4, R5 , R6, R7, R8, R9, R10, R10a, R11 and R12 are as defined herein. These compounds are inhibitors of Factor Xa and thus are useful as anticoagulants. A method for treating cardiovascular diseases associated with thromboses is also provided.

Abstract: Compound of the formula are inhibitors of the enzyme Factor Xa. These compounds are useful as anticoagulants in the treatment of cardiovascular diseases associated with thromboses.

Abstract: Compound of the formula 1

Abstract: Lactam inhibitors are provided which have the structure 1

Abstract: Caprolactam inhibitors are provided which have the structure including pharmaceutically acceptable salts thereof and all stereoisomers thereof, and prodrugs thereof, wherein n is 1 to 5; and and Y R1, R2, R3, R5, R5a, R6, R7, R8, R9 and R10 are as defined herein. These compounds are inhibitors of Factor Xa and thus are useful as anticoagulants. A method for treating cardiovascular diseases associated with thromboses is also provided.